Concord Biotech Limited Total Liabilities

Latest as of September 2025: Rs1.96 Billion INR ≈ $21.24 Million USD

Concord Biotech Limited total liabilities. Based on the latest financial reports, Concord Biotech Limited (CONCORDBIO) has total liabilities worth Rs1.96 Billion INR (≈ $21.24 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check CONCORDBIO cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Concord Biotech Limited (2020–2025)

Total liabilities of Concord Biotech Limited from 2020 to 2025. This chart illustrates how Concord Biotech Limited's total liabilities have evolved over time, based on quarterly financial data.

Concord Biotech Limited Competitors by Total Liabilities

The table below lists competitors of Concord Biotech Limited ranked by their total liabilities.

Company	Country	Total Liabilities
Dalian Huarui Heavy Industry Group Co Ltd SHE:002204	China	CN¥19.40 Billion
Zhejiang Construction Investment Group Co Ltd SHE:002761	China	CN¥107.64 Billion
Shenzhen Injoinic Technology Co. Ltd. A SHG:688209	China	CN¥215.38 Million
TriMas Corporation NASDAQ:TRS	USA	$803.04 Million
Tianjin Chase Sun Pharmaceutical Co Ltd SHE:300026	China	CN¥1.65 Billion
Lotte Chemical Corp KO:011170	Korea	₩13.78 Trillion
Vistance Networks, Inc. NASDAQ:VISN	USA	$991.00 Million
Orezone Gold Corporation AU:ORE	Australia	AU$742.92 Million

Liability Composition Analysis (2020–2025)

This chart breaks down Concord Biotech Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Concord Biotech Limited assets under control.

Liquidity & Leverage Metrics

Concord Biotech Limited Total Liabilities Ratios Explained

Concord Biotech Limited total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric	Value	Description
Current Ratio	6.97	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.11	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.10	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Concord Biotech Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Concord Biotech Limited (2020–2025)

The table below shows the annual total liabilities of Concord Biotech Limited from 2020 to 2025.

Year	Total Liabilities	Change
2025-03-31	Rs2.22 Billion ≈ $23.96 Million	+27.27%
2024-03-31	Rs1.74 Billion ≈ $18.82 Million	-22.29%
2023-03-31	Rs2.24 Billion ≈ $24.22 Million	+6.88%
2022-03-31	Rs2.10 Billion ≈ $22.66 Million	+14.41%
2021-03-31	Rs1.83 Billion ≈ $19.81 Million	+7.57%
2020-03-31	Rs1.70 Billion ≈ $18.42 Million	--

About Concord Biotech Limited

NSE:CONCORDBIO India Biotechnology

Market Cap

$1.39 Billion

Rs128.46 Billion INR

Market Cap Rank

#7248 Global

#351 in India

Share Price

Rs1227.90

Change (1 day)

+5.54%

52-Week Range

Rs1014.80 - Rs1587.50

All Time High

Rs2601.10